Expanding the clinical indications for α1-antitrypsin therapy

Molecular Medicine

Volumn 18, Issue 6, 2012, Pages 957-970

  Lewis, Eli C ^a  

^a BEN GURION UNIVERSITY OF THE NEGEV   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA 1 ANTITRYPSIN; CASPASE 3; ELASTASE; HEAT SHOCK PROTEIN 70; HUMAN IMMUNODEFICIENCY VIRUS PROTEIN; INTERLEUKIN 1; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; INTERLEUKIN 10; INTERLEUKIN 1BETA CONVERTING ENZYME; INTERLEUKIN 8; LOW DENSITY LIPOPROTEIN; MYELOBLASTIN; PROTEINASE; VASCULOTROPIN;

ACUTE HEART INFARCTION; ALPHA 1 ANTITRYPSIN DEFICIENCY; ANTIBACTERIAL ACTIVITY; ANTIINFLAMMATORY ACTIVITY; ANTIVIRAL ACTIVITY; APOPTOSIS; ARTICLE; CELL MATURATION; CHRONIC OBSTRUCTIVE LUNG DISEASE; CYSTIC FIBROSIS; CYTOKINE PRODUCTION; CYTOKINE RELEASE; DENDRITIC CELL; DISEASE COURSE; DRUG EFFICACY; DRUG SAFETY; ENTERITIS; ENZYME ACTIVITY; ENZYME INHIBITION; GENE THERAPY; GRAFT REJECTION; GRAFT VERSUS HOST REACTION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IN VITRO STUDY; IN VIVO STUDY; INFLUENZA; INSULIN DEPENDENT DIABETES MELLITUS; ISCHEMIC HEART DISEASE; LIPID RAFT; LYMPHOCYTE DIFFERENTIATION; MULTIPLE SCLEROSIS; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OPPORTUNISTIC INFECTION; PATIENT COMPLIANCE; PREGNANCY COMPLICATION; PRIORITY JOURNAL; PROTEIN BINDING; REGULATORY T LYMPHOCYTE; RHEUMATOID ARTHRITIS; TREATMENT INDICATION;

ALPHA 1-ANTITRYPSIN; ALPHA 1-ANTITRYPSIN DEFICIENCY; ANTI-INFLAMMATORY AGENTS; HUMANS; INFLAMMATION; TRANSLATIONAL MEDICAL RESEARCH;

EID: 84865214922     PISSN: 10761551     EISSN: None     Source Type: Journal    
DOI: 10.2119/molmed.2011.00196     Document Type: Article

References (163)

1. Niemann H, Kues WA. (2003) Application of transgenesis in livestock for agriculture and biomedicine. Anim. Reprod. Sci. 79:291-317.
2. Stoller JK, Aboussouan LS. (2012) A review of alpha1-antitrypsin deficiency. Am. J. Respir. Crit. Care Med. 185:246-59.
3. Jie Z, et al. (2003) Protective effects of alpha 1-antitrypsin on acute lung injury in rabbits induced by endotoxin. Chin. Med. J. 116:1678-82.
4. Pott GB, Chan ED, Dinarello CA, Shapiro L. (2009) Alpha-1-antitrypsin is an endogenous inhibitor of proinflammatory cytokine production in whole blood. J. Leukoc. Biol. 85:886-95.
5. Tilg H, Vannier E, Vachino G, Dinarello CA, Mier JW. (1993) Antiinflammatory properties of hepatic acute phase proteins: preferential induction of interleukin 1 (IL-1) receptor antagonist over IL-1 beta synthesis by human peripheral blood mononuclear cells. J. Exp. Med. 178:1629-36.
6. Subramanian S, et al. (2011) Sustained expression of circulating human alpha-1 antitrypsin reduces inflammation, increases CD4+FoxP3+ Treg cell population and prevents signs of experimental autoimmune encephalomyelitis in mice. Metab. Brain Dis. 26:107-13.
7. Koulmanda M, et al. (2008) Curative and beta cell regenerative effects of alpha1-antitrypsin treatment in autoimmune diabetic NOD mice. Proc. Natl. Acad. Sci. U. S. A. 105:16242-7.
8. Lewis EC, et al. (2008) Alpha1-antitrypsin monotherapy induces immune tolerance during islet allograft transplantation in mice. Proc. Natl. Acad. Sci. U. S. A. 105:16236-41.
9. Ozeri E, Mizrahi M, Shahaf G, Lewis EC. (2012) α-1 Antitrypsin promotes semimature, IL-10producing and readily migrating tolerogenic dendritic cells. J. Immunol. 189:146-53.
10. Lewis EC, Shapiro L, Bowers OJ, Dinarello CA. (2005) Alpha1-antitrypsin monotherapy prolongs islet allograft survival in mice. Proc. Natl. Acad. Sci. U. S. A. 102:12153-8.
11. Marcondes AM, et al. (2011) Inhibition of IL-32 activation by alpha-1 antitrypsin suppresses alloreactivity and increases survival in an allogeneic murine marrow transplantation model. Blood. 118:5031-9.
12. Tawara I, et al. (2012) Alpha-1-antitrypsin monotherapy reduces graft-versus-host disease after experimental allogeneic bone marrow transplantation. Proc. Natl. Acad. Sci. U. S. A. 109:564-9.
13. Arora PK, Miller HC, Aronson LD. (1978) Alpha1-antitrypsin is an effector of immunological stasis. Nature. 274:589-90.
14. Wewers MD, et al. (1987) Replacement therapy for alpha 1-antitrypsin deficiency associated with emphysema. N. Engl. J. Med. 316:1055-62.
15. Gotzsche PC, Johansen HK. (2010) Intravenous alpha-1 antitrypsin augmentation therapy: systematic review. Dan. Med. Bull. 57:A4175.
16. Janciauskiene SM, et al. (2011) The discovery of alpha1-antitrypsin and its role in health and disease. Respir. Med. 105:1129-39.
17. Larsson A, Palm M, Hansson LO, Basu S, Axelsson O. (2008) Reference values for alpha1-acid glycoprotein, alpha1-antitrypsin, albumin, haptoglobin, C-reactive protein, IgA, IgG and IgM during pregnancy. Acta. Obstet. Gynecol. Scand. 87:1084-8.
18. Paczek L, Michalska W, Bartlomiejczyk I. (2008) Trypsin, elastase, plasmin and MMP-9 activity in the serum during the human ageing process. Age Ageing. 37:318-23.
19. Dhami R, et al. (1999) Pulmonary epithelial expression of human alpha1-antitrypsin in transgenic mice results in delivery of alpha1antitrypsin protein to the interstitium. J. Mol. Med. (Berl.). 77:377-85.
20. Tuder RM, Janciauskiene SM, Petrache I. (2010) Lung disease associated with alpha1-antitrypsin deficiency. Proc. Am. Thorac. Soc. 7:381-6.
21. de Serres FJ, Blanco I, Fernandez-Bustillo E. (2007) PI S and PI Z alpha-1 antitrypsin deficiency worldwide: a review of existing genetic epidemiological data. Monaldi Arch. Chest Dis. 67:184-208.
22. Perlmutter DH. (2011) Alpha-1-antitrypsin deficiency: importance of proteasomal and autophagic degradative pathways in disposal of liver disease-associated protein aggregates. Annu. Rev. Med. 62:333-45.
23. Wang D, et al. (2011) Deletion of Serpina1a, a murine alpha1-antitrypsin ortholog, results in embryonic lethality. Exp. Lung Res. 37:291-300.
24. Lee WL, Downey GP. (2001) Leukocyte elastase: physiological functions and role in acute lung injury. Am. J. Respir. Crit. Care Med. 164:896-904.
25. Perlmutter DH, et al. (1990) Endocytosis and degradation of alpha 1-antitrypsin-protease complexes is mediated by the serpin-enzyme complex (SEC) receptor. J. Biol. Chem. 265:16713-6.
26. Joslin G, Fallon RJ, Bullock J, Adams SP, Perlmutter DH. (1991) The SEC receptor recognizes a pentapeptide neodomain of alpha 1-antitrypsinprotease complexes. J. Biol. Chem. 266:11282-8.
27. Janciauskiene S, Zelvyte I, Jansson L, Stevens T. (2004) Divergent effects of alpha1-antitrypsin on neutrophil activation, in vitro. Biochem. Biophys. Res. Commun. 315:288-96.
28. Janciauskiene S, Moraga F, Lindgren S. (2001) C-terminal fragment of alpha1-antitrypsin activates human monocytes to a pro-inflammatory state through interactions with the CD36 scavenger receptor and LDL receptor. Atherosclerosis. 158:41-51.
29. Subramaniyam D, et al. (2006) C-36 peptide, a degradation product of alpha1-antitrypsin, modulates human monocyte activation through LPS signaling pathways. Int. J. Biochem. Cell Biol. 38:563-75.
30. Janciauskiene S, Wright HT, Lindgren S. (1999) Atherogenic properties of human monocytes induced by the carboxyl terminal proteolytic fragment of alpha-1-antitrypsin. Atherosclerosis. 147:263-75.
31. Dichtl W, et al. (2000) The carboxyl-terminal fragment of alpha1-antitrypsin is present in atherosclerotic plaques and regulates inflammatory transcription factors in primary human monocytes. Mol. Cell. Biol. Res. Commun. 4:50-61.
32. Shpacovitch V, Feld M, Hollenberg MD, Luger TA, Steinhoff M. (2008) Role of proteaseactivated receptors in inflammatory responses, innate and adaptive immunity. J. Leukoc. Biol. 83:1309-22.
33. Fields RC, et al. (2003) Protease-activated receptor-2 signaling triggers dendritic cell development. Am. J. Pathol. 162:1817-22.
34. Shah R. (2009) Protease-activated receptors in cardiovascular health and diseases. Am. Heart J. 157:253-62.
35. Vergnolle N, et al. (2006) A role for proteinaseactivated receptor-1 in inflammatory bowel diseases. J. Clin. Invest. 116:2056.
36. Noorbakhsh F, et al. (2006) Proteinase-activated receptor 2 modulates neuroinflammation in experimental autoimmune encephalomyelitis and multiple sclerosis. J. Exp. Med. 203:425-35.
37. Yoshida K, et al. (2005) Aggrecanase-1 (ADAMTS-4) interacts with alpha1-antitrypsin. Biochim. Biophys. Acta. 1725:152-9.
38. Liu Z, et al. (2000) The serpin alpha1-proteinase inhibitor is a critical substrate for gelatinaseB/MMP-9 in vivo. Cell. 102:647-55.
39. Muroski ME, et al. (2008) Matrix metalloproteinase-9/ gelatinase B is a putative therapeutic target of chronic obstructive pulmonary disease and multiple sclerosis. Curr. Pharm. Biotechnol. 9:34-46.
40. Al-Omari M, et al. (2011) Acute-phase protein alpha1-antitrypsin inhibits neutrophil calpain I and induces random migration. Mol. Med. 17:865-74.
41. Segel GB, Halterman MW, Lichtman MA. (2011) The paradox of the neutrophil's role in tissue injury. J. Leukoc. Biol. 89:359-72.
42. Bergin DA, et al. (2010) Alpha-1 antitrypsin regulates human neutrophil chemotaxis induced by soluble immune complexes and IL-8. J. Clin. Invest. 120:4236-50.
43. Miyake Y, Yamasaki S. (2012) Sensing necrotic cells. Adv. Exp. Med. Biol. 738:144-52.
44. Tsan MF. (2011) Heat shock proteins and high mobility group box 1 protein lack cytokine func-tion. J. Leukoc. Biol. 89:847-53.
45. Finotti P, Pagetta A. (2004) A heat shock protein70 fusion protein with alpha1-antitrypsin in plasma of type 1 diabetic subjects. Biochem. Biophys. Res. Commun. 315:297-305.
46. Subramaniyam D, et al. (2010) Cholesterol rich lipid raft microdomains are gateway for acute phase protein, SERPINA1. Int. J. Biochem. Cell Biol. 42:1562-70.
47. Correale M, Brunetti ND, De Gennaro L, Di Biase M. (2008) Acute phase proteins in atherosclerosis (acute coronary syndrome). Cardiovasc. Hematol. Agents Med. Chem. 6:272-7.
48. Mashiba S, et al. (2001) In vivo complex formation of oxidized alpha(1)-antitrypsin and LDL. Arterioscler. Thromb. Vasc. Biol. 21:1801-8.
49. Talmud PJ, et al. (2003) Progression of atherosclerosis is associated with variation in the alpha1antitrypsin gene. Arterioscler. Thromb. Vasc. Biol. 23:644-9.
50. Shapiro L, Pott GB, Ralston AH. (2001) Alpha-1antitrypsin inhibits human immunodeficiency virus type 1. FASEB J. 15:115-22.
51. Munch J, et al. (2007) Discovery and optimization of a natural HIV-1 entry inhibitor targeting the gp41 fusion peptide. Cell. 129:263-75.
52. Bryan CL, et al. (2010) HIV infection is associated with reduced serum alpha-1-antitrypsin concen-trations. Clin. Invest. Med. 33:E384-9.
53. Congote LF. (2006) The C-terminal 26-residue peptide of serpin A1 is an inhibitor of HIV-1. Biochem. Biophys. Res. Commun. 343:617-22.
54. Forssmann WG, et al. (2010) Short-term monotherapy in HIV-infected patients with a virus entry inhibitor against the gp41 fusion peptide. Sci. Transl. Med. 2:63re63.
55. Petrache I, et al. (2006) A novel antiapoptotic role for alpha1-antitrypsin in the prevention of pulmonary emphysema. Am. J. Respir. Crit. Care Med. 173:1222-8.
56. Tuder RM, Yoshida T, Fijalkowka I, Biswal S, Petrache I. (2006) Role of lung maintenance program in the heterogeneity of lung destruction in emphysema. Proc. Am. Thorac. Soc. 3:673-9.
57. Zelvyte I, Stevens T, Westin U, Janciauskiene S. (2004) Alpha1-antitrypsin and its C-terminal fragment attenuate effects of degranulated neutrophil-conditioned medium on lung cancer HCC cells, in vitro. Cancer Cell Int. 4:7.
58. Kurtagic E, Jedrychowski MP, Nugent MA. (2009) Neutrophil elastase cleaves VEGF to generate a VEGF fragment with altered activity. Am. J. Physiol. Lung Cell Mol. Physiol. 296:L534-46.
59. Ikari Y, Fujikawa K, Yee KO, Schwartz SM. (2000) Alpha(1)-proteinase inhibitor, alpha(1)antichymotrypsin, or alpha(2)-macroglobulin is required for vascular smooth muscle cell spreading in three-dimensional fibrin gel. J. Biol. Chem. 275:12799-805.
60. Petrache I, et al. (2006) Alpha-1 antitrypsin inhibits caspase-3 activity, preventing lung en-dothelial cell apoptosis. Am. J. Pathol. 169:1155-66.
61. Tuder RM, et al. (2003) Oxidative stress and apo-ptosis interact and cause emphysema due to vascular endothelial growth factor receptor blockade. Am. J. Respir. Cell Mol. Biol. 29:88-97.
62. Elias JA, Kang MJ, Crothers K, Homer R, Lee CG. (2006) State of the art: mechanistic heterogeneity in chronic obstructive pulmonary disease: insights from transgenic mice. Proc. Am. Thorac. Soc. 3:494-8.
63. Kasahara Y, et al. (2001) Endothelial cell death and decreased expression of vascular endothelial growth factor and vascular endothelial growth factor receptor 2 in emphysema. Am. J. Respir. Crit. Care Med. 163:737-44.
64. Taraseviciene-Stewart L, et al. (2001) Inhibition of the VEGF receptor 2 combined with chronic hypoxia causes cell death-dependent pulmonary endothelial cell proliferation and severe pulmonary hypertension. FASEB J. 15:427-38.
65. Wenger RH, Rolfs A, Marti HH, Bauer C, Gassmann M. (1995) Hypoxia, a novel inducer of acute phase gene expression in a human hepatoma cell line. J. Biol. Chem. 270:27865-70.
66. Wewers MD. (2004) Alpha1-antitrypsin deficiency: more than a protease imbalance? Chest. 125:1607-9.
67. Zhong X, et al. (2007) Reciprocal generation of Th1/Th17 and T(reg) cells by B1 and B2 B cells. Eur. J. Immunol. 37:2400-4.
68. Lee WW, et al. (2010) Regulating human Th17 cells via differential expression of IL-1 receptor. Blood. 115:530-40.
69. Pemberton PA, et al. (2006) Inhaled recombinant alpha 1-antitrypsin ameliorates cigarette smokeinduced emphysema in the mouse. COPD. 3:101-8.
70. Hadzic R, et al. (2006) Alpha1-antitrypsin inhibits Moraxella catarrhalis MID protein-induced tonsillar B cell proliferation and IL-6 release. Immunol. Lett. 102:141-7.
71. Blank CA, Brantly M. (1994) Clinical features and molecular characteristics of alpha 1-antitrypsin deficiency. Ann. Allergy. 72:105-20.
72. Yaghmaei M, et al. (2009) Serum trypsin inhibitory capacity in normal pregnancy and gestational diabetes mellitus. Diabetes Res. Clin. Pract. 84:201-4.
73. Ekeowa UI, Marciniak SJ, Lomas DA. (2011) Alpha(1)-antitrypsin deficiency and inflammation. Expert Rev. Clin. Immunol. 7:243-52.
74. Schmechel DE, Edwards CL. (2012) Fibromyalgia, mood disorders, and intense creative energy: A1AT polymorphisms are not always silent. Neurotoxicology. 2012 March 10 [Epub ahead of print]
75. Schmechel DE. (2007) Art, alpha-1-antitrypsin polymorphisms and intense creative energy: blessing or curse? Neurotoxicology. 28:899-914.
76. Dinarello CA. (2010) Anti-inflammatory agents: present and future. Cell. 140:935-50.
77. Desouza CV. (2010) An overview of salsalate as a potential antidiabetic therapy. Drugs Today (Barc.). 46:847-53.
78. Larsen CM, et al. (2007) [Interleukin-1 receptor antagonist-treatment of patients with type 2 diabetes]. Ugeskr. Laeger. 169:3868-71.
79. Geiler J, McDermott MF. (2010) Gevokizumab, an anti-IL-1beta mAb for the potential treatment of type 1 and 2 diabetes, rheumatoid arthritis and cardiovascular disease. Curr. Opin. Mol. Ther. 12:755-69.
80. Donath MY, Shoelson SE. (2011) Type 2 diabetesas an inflammatory disease. Nat. Rev. Immunol. 11:98-107.
81. Bendtzen K, et al. (1986) Cytotoxicity of human pI 7 interleukin-1 for pancreatic islets of Langerhans. Science. 232:1545-7.
82. Kalis M, Kumar R, Janciauskiene S, Salehi A, Cilio CM. (2010) Alpha 1-antitrypsin enhances insulin secretion and prevents cytokine-mediated apoptosis in pancreatic beta-cells. Islets. 2:185-9.
83. Weir GC, Koulamnda M. (2009) Control of inflammation with alpha1-antitrypsin: a potential treatment for islet transplantation and new-onset type 1 diabetes. Curr. Diab. Rep. 9:100-2.
84. Pileggi A, et al. (2008) Alpha-1 antitrypsin treatment of spontaneously diabetic nonobese diabetic mice receiving islet allografts. Transplant Proc. 40:457-8.
85. Strom TB. (2005) Saving islets from allograft rejection. Proc. Natl. Acad. Sci. U. S. A. 102:12651-2.
86. Papaccio G, Pedulla M, Ammendola E, Todaro M. (2002) Cytokine regulatory effects on alpha-1 proteinase inhibitor expression in NOD mouse islet endothelial cells. J. Cell. Biochem. 85:123-30.
87. Sandstrom CS, et al. (2008) An association between type 2 diabetes and alpha-antitrypsin deficiency. Diabet. Med. 25:1370-3.
88. Phillips B, Trucco M, Giannoukakis N. (2011) Current state of type 1 diabetes immunotherapy: incremental advances, huge leaps, or more of the same? Clin. Dev. Immunol. 2011:432016.
89. Donath MY, Mandrup-Poulsen T. (2008) The use of interleukin-1-receptor antagonists in the treatment of diabetes mellitus. Nat. Clin. Pract. Endocrinol. Metab. 4:240-1.
90. Sumpter KM, Adhikari S, Grishman EK, White PC. (2011) Preliminary studies related to anti-interleukin-1beta therapy in children with newly diagnosed type 1 diabetes. Pediatr. Diabetes. 12:656-67.
91. Hashemi M, Naderi M, Rashidi H, Ghavami S. (2007) Impaired activity of serum alpha-1antitrypsin in diabetes mellitus. Diabetes Res. Clin. Pract. 75:246-8.
92. Lisowska-Myjak B, Pachecka J, Kaczynska B, Miszkurka G, Kadziela K. (2006) Serum protease inhibitor concentrations and total antitrypsin activity in diabetic and non-diabetic children during adolescence. Acta Diabetol. 43:88-92.
93. Bristow CL, Di Meo F, Arnold RR. (1998) Specific activity of alpha1proteinase inhibitor and alpha2macroglobulin in human serum: application to insulin-dependent diabetes mellitus. Clin. Immunol. Immunopathol. 89:247-59.
94. Sandler M, Gemperli BM, Hanekom C, Kuhn SH. (1988) Serum alpha 1-protease inhibitor in diabetes mellitus: reduced concentration and impaired activity. Diabetes Res. Clin. Pract. 5:249-55.
95. Hall P, Tryon E, Nikolai TF, Roberts RC. (1986) Functional activities and nonenzymatic glycosylation of plasma proteinase inhibitors in diabetes. Clin. Chim. Acta. 160:55-62.
96. Lu Y, et al. (2006) Alpha1-antitrypsin gene therapy modulates cellular immunity and efficiently prevents type 1 diabetes in nonobese diabetic mice. Hum. Gene Ther. 17:625-34.
97. Ma H, et al. (2010) Intradermal alpha1-antitrypsin therapy avoids fatal anaphylaxis, prevents type 1 diabetes and reverses hyperglycaemia in the NOD mouse model of the disease. Diabetologia. 53:2198-204.
98. Zhang B, et al. (2007) Alpha1-antitrypsin protects beta-cells from apoptosis. Diabetes. 56:1316-23.
99. Lou J, et al. (1999) Expression of alpha-1 proteinase inhibitor in human islet microvascular endothelial cells. Diabetes. 48:1773-8.
100. Bosco D, et al. (2005) Expression and secretion of alpha1-proteinase inhibitor are regulated by proinflammatory cytokines in human pancreatic islet cells. Diabetologia. 48:1523-33.
101. Fujita M, Nakanishi Y. (2007) The pathogenesis of COPD: lessons learned from in vivo animal models. Med. Sci. Monit. 13:RA19-24.
102. Pizzutto SJ, Upham JW, Yerkovich ST, Chang AB. (2010) Inhaled non-steroid anti-inflammatories for children and adults with bronchiectasis. Cochrane Database Syst. Rev. CD007525.
103. Kerem E, et al. (2009) Safety and efficacy of inhaled human alpha-1 antitrypsin (AAT) in cystic fibrosis (CF): a report of a phase II clinical study [abstract]. Am. J. Respir. Crit. Care Med. 179:A1185.
104. Sly PD, et al. (2009) Lung disease at diagnosis in infants with cystic fibrosis detected by newborn screening. Am. J. Respir. Crit. Care Med. 180:146-52.
105. Siekmeier R. (2010) Lung deposition of inhaled alpha-1-proteinase inhibitor (alpha 1-PI): problems and experience of alpha1-PI inhalation therapy in patients with hereditary alpha1-PI deficiency and cystic fibrosis. Eur. J. Med. Res. 15 (Suppl. 2):164-74.
106. Hagen LE, et al. (2011) High alpha-1 antitrypsinclearance predicts severity of gut graft-versushost disease (GVHD) in children. Pediatr. Transplant. 15:659-63.
107. Dinarello CA. (2011) Interleukin-1 in the pathogenesis and treatment of inflammatory diseases. Blood. 117:3720-32.
108. Antin JH, et al. (1994) Recombinant human interleukin-1 receptor antagonist in the treatment of steroid-resistant graft-versus-host disease. Blood. 84:1342-8.
109. Antin JH, et al. (2002) Interleukin-1 blockade does not prevent acute graft-versus-host disease: results of a randomized, double-blind, placebo-controlled trial of interleukin-1 receptor antagonist in allogeneic bone marrow transplantation. Blood. 100:3479-82.
110. Zeiser R, Penack O, Holler E, Idzko M. (2011) Danger signals activating innate immunity in graft-versus-host disease. J. Mol. Med. (Berl). 89:833-45.
111. McInnes IB, O'Dell JR. (2010) State-of-the-art: rheumatoid arthritis. Ann. Rheum. Dis. 69:1898-906.
112. Chidwick K, et al. (1994) Relationship between alpha 1-antitrypsin inactivation and tumor necrosis factor alpha concentration in the synovial fluid of patients with rheumatoid arthritis. Arthritis Rheum. 37:1723-6.
113. Kakimoto K, Matsukawa A, Yoshinaga M, Nakamura H. (1995) Suppressive effect of a neutrophil elastase inhibitor on the development of collagen-induced arthritis. Cell Immunol. 165:26-32.
114. Grimstein C, et al. (2011) Alpha-1 antitrypsin protein and gene therapies decrease autoimmunity and delay arthritis development in mouse model. J. Transl. Med. 9:21.
115. Grimstein C, et al. (2010) Combination of alpha1 antitrypsin and doxycycline suppresses collagen-induced arthritis. J. Gene Med. 12:35-44.
116. Wee Yong V. (2010) Inflammation in neurological disorders: a help or a hindrance? Neuroscientist. 16:408-20.
117. Lolin YI, Ward AM. (1995) Alpha-1-antitrypsin phenotypes and associated disease patterns in neurological patients. Acta Neurol. Scand. 91:394-8.
118. McCombe PA, et al. (1985) Alpha-1 antitrypsin phenotypes in demyelinating disease: an association between demyelinating disease and the allele PiM3. Ann. Neurol. 18:514-6.
119. Pearl GS, Mullins RE. (1985) Alpha 1-antitrypsin in cerebrospinal fluid of patients with neurologic diseases. Arch. Neurol. 42:775-7.
120. Folwaczny C, et al. (1998) Alpha1-antitrypsin alleles and phenotypes in patients with inflammatory bowel disease. Scand. J. Gastroenterol. 33:78-81.
121. Kotlowski R, Bernstein CN, Silverberg MS, Krause DO. (2008) Population-based casecontrol study of alpha 1-antitrypsin and SLC11A1 in Crohn's disease and ulcerative colitis. Inflamm. Bowel Dis. 14:1112-7.
122. Molmenti EP, Perlmutter DH, Rubin DC. (1993) Cell-specific expression of alpha 1-antitrypsin in human intestinal epithelium. J. Clin. Invest. 92:2022-34.
123. Turer AT, Hill JA. (2010) Pathogenesis of myocardial ischemia-reperfusion injury and rationale for therapy. Am. J. Cardiol. 106:360-8.
124. Jiang B, Liao R. (2010) The paradoxical role of inflammation in cardiac repair and regeneration. J. Cardiovasc. Transl. Res. 3:410-6.
125. Toldo S, et al. (2011) Alpha-1 antitrypsin inhibits caspase-1 and protects from acute myocardialischemia-reperfusion injury. J. Mol. Cell. Cardiol. 51:244-51.
126. Daemen MA, et al. (2000) Functional protection by acute phase proteins alpha(1)-acid glycoprotein and alpha(1)-antitrypsin against ischemia/ reperfusion injury by preventing apoptosis and inflammation. Circulation. 102:1420-6.
127. Kanayama N, Kamijo H, Terao T, Horiuchi K, Fujimoto D. (1986) The relationship between trypsin activity in amniotic fluid and premature rupture of membranes. Am. J. Obstet. Gynecol. 155:1043-8.
128. Izumi-Yoneda N, et al. (2009) Alpha 1 antitrypsin activity is decreased in human amnion in premature rupture of the fetal membranes. Mol. Hum. Reprod. 15:49-57.
129. Aboussouan LS, Stoller JK. (2009) Detection of alpha-1 antitrypsin deficiency: a review. Respir. Med. 103:335-41.
130. Churg A, Wang RD, Xie C, Wright JL. (2003) Alpha-1-antitrypsin ameliorates cigarette smoke-induced emphysema in the mouse. Am. J. Respir. Crit. Care Med. 168:199-207.
131. Lieberman J. (2000) Augmentation therapy reduces frequency of lung infections in antitrypsin deficiency: a new hypothesis with supporting data. Chest. 118:1480-5.
132. Huang H, et al. (2004) Alpha1-antitrypsin inhibits angiogenesis and tumor growth. Int. J. Cancer. 112:1042-8.
133. Yavelow J, Tuccillo A, Kadner SS, Katz J, Finlay TH. (1997) Alpha 1-antitrypsin blocks the release of transforming growth factor-alpha from MCF-7 human breast cancer cells. J. Clin. Endocrinol. Metab. 82:745-52.
134. Sallenave JM. (2002) Antimicrobial activity of antiproteinases. Biochem. Soc. Trans. 30:111-5.
135. Forney JR, Yang S, Healey MC. (1997) Synergistic anticryptosporidial potential of the combination alpha-1-antitrypsin and paromomycin. Antimicrob. Agents Chemother. 41:2006-8.
136. Miyamoto Y, et al. (2000) Novel functions of human alpha(1)-protease inhibitor after S-nitrosylation: inhibition of cysteine protease and antibacterial activity. Biochem. Biophys. Res. Commun. 267:918-23.
137. Porat R, Clark BD, Wolff SM, Dinarello CA. (1991) Enhancement of growth of virulent strains of Escherichia coli by interleukin-1. Science. 254:430-2.
138. Riveau GR, Novitsky TJ, Roslansky PF, Dinarello CA, Warren HS. (1987) Role of interleukin-1 in augmenting serum neutralization of bacterial lipopolysaccharide. J. Clin. Microbiol. 25:889-92.
139. Chan ED, et al. (2007) Alpha-1-antitrypsin (AAT) anomalies are associated with lung disease due to rapidly growing mycobacteria and AAT inhibits Mycobacterium abscessus infection of macrophages. Scand. J. Infect. Dis. 39:690-6.
140. Wencker M, Fuhrmann B, Banik N, Konietzko N. (2001) Longitudinal follow-up of patients with alpha(1)-protease inhibitor deficiency before and during therapy with IV alpha(1)protease inhibitor. Chest. 119:737-44.
141. Blanco I, et al. (2008) Long-term augmentation therapy with alpha-1 antitrypsin in an MZ-AAT severe persistent asthma. Monaldi Arch. Chest Dis. 69:178-82.
142. Mordwinkin NM, Louie SG. (2007) Aralast: an alpha 1-protease inhibitor for the treatment of alpha-antitrypsin deficiency. Expert Opin. Pharmacother. 8:2609-14.
143. Petrache I, Hajjar J, Campos M. (2009) Safety and efficacy of alpha-1-antitrypsin augmentation therapy in the treatment of patients with alpha-1-antitrypsin deficiency. Biologics. 3:193-204.
144. Griese M, et al. (2007) Alpha1-antitrypsin inhalation reduces airway inflammation in cystic fibrosis patients. Eur. Respir. J. 29:240-50.
145. Janciauskiene SM, Nita IM, Stevens T. (2007) Alpha1-antitrypsin, old dog, new tricks: alpha1antitrypsin exerts in vitro anti-inflammatory activity in human monocytes by elevating cAMP. J. Biol. Chem. 282:8573-82.
146. Wouters D, Wagenaar-Bos I, van Ham M, Zeerleder S. (2008) C1 inhibitor: just a serine protease inhibitor? New and old considerations on therapeutic applications of C1 inhibitor. Expert Opin. Biol. Ther. 8:1225-40.
147. Wiedermann Ch J, Romisch J. (2002) The antiinflammatory actions of antithrombin: a review. Acta Med. Austriaca. 29:89-92.
148. Shahaf G, et al. (2011) Alpha-1-antitrypsin genedelivery reduces inflammation, increases T-regulatory cell population size and prevents islet allograft rejection. Mol. Med. 17:1000-11.
149. Stockley RA. (2010) Emerging drugs for alpha1-antitrypsin deficiency. Expert Opin. Emerg. Drugs. 15:685-94.
150. Flotte TR, Mueller C. (2011) Gene therapy for alpha-1 antitrypsin deficiency. Hum. Mol. Genet. 20:R87-92.
151. Stoll SM, et al. (2001) Epstein-Barr virus/human vector provides high-level, long-term expression of alpha1-antitrypsin in mice. Mol. Ther. 4:122-9.
152. Karnaukhova E, Ophir Y, Golding B. (2006) Recombinant human alpha-1 proteinase inhibitor: towards therapeutic use. Amino Acids. 30:317-32.
153. Cantin AM, Woods DE, Cloutier D, Dufour EK, Leduc R. (2002) Polyethylene glycol conjugation at Cys232 prolongs the half-life of alpha1 proteinase inhibitor. Am. J. Respir. Cell Mol. Biol. 27:659-65.
154. Zbikowska HM, et al. (2002) Uromodulin promoter directs high-level expression of biologically active human alpha1-antitrypsin into mouse urine. Biochem. J. 365:7-11.
155. Hedin SG. (1906) Trypsin and antitrypsin. Biochem. J. 1:474-83.
156. Blanco I, Lara B, de Serres F. (2011) Efficacy of alpha1-antitrypsin augmentation therapy in conditions other than pulmonary emphysema. Orphanet J. Rare Dis. 6:14.
157. Chen GY, Nunez G. (2010) Sterile inflammation: sensing and reacting to damage. Nat. Rev. Immunol. 10:826-37.
158. Eltzschig HK, Carmeliet P. (2011) Hypoxia and inflammation. N. Engl. J. Med. 364:656-65.
159. Song S, et al. (2004) Recombinant adeno-associated virus-mediated alpha-1 antitrypsin gene therapy prevents type I diabetes in NOD mice. Gene Ther. 11:181-6.
160. Loganathan G, et al. (2010) Culture of impure human islet fractions in the presence of alpha-1 antitrypsin prevents insulin cleavage and improves islet recovery. Transplant. Proc. 42:2055-7.
161. Congote LF, Temmel N, Sadvakassova G, Dobocan MC. (2008) Comparison of the effects of serpin A1, a recombinant serpin A1-IGF chimera and serpin A1 C-terminal peptide on wound healing. Peptides. 29:39-46.
162. Nita I, Hollander C, Westin U, Janciauskiene SM. (2005) Prolastin, a pharmaceutical preparation of purified human alpha1-antitrypsin, blocks endotoxin-mediated cytokine release. Respir. Res. 6:12.
163. Blanchard V, et al. (2011) N-glycosylation and biological activity of recombinant human alpha1antitrypsin expressed in a novel human neuronal cell line. Biotechnol. Bioeng. 108:2118-28.